MIPLA, or methylisopropyllysergamide, is a semi-synthetic compound structurally related to LSD. First synthesized by Albert Hofmann, MIPLA is one of many lysergamide analogs designed to explore the impact of subtle amide substitutions on psychedelic activity. It retains the core ergoline structure of LSD but features a methyl and isopropyl group substitution at the amide nitrogen.

• Chemical Classification
  MIPLA belongs to the lysergamide class of compounds, structurally similar to LSD. These compounds are derived from lysergic acid and differ in their amide substitutions, which influence receptor binding and psychoactive effects.

• Origin of Synthesis
  It was initially synthesized in the 1950s by Albert Hofmann’s team at Sandoz during their investigation of LSD analogs. It was part of a broader effort to identify compounds with similar or improved therapeutic and psychotropic profiles.

• Molecular Behavior
  MIPLA is known to bind to serotonin receptors, primarily 5‑HT2A, which plays a major role in mediating hallucinogenic experiences. Its receptor affinity is similar to LSD but with lower potency.

• Psychoactive Profile
  The effects of MIPLA mirror those of LSD in terms of visuals, time distortion, and altered cognition, though typically reported to be milder and shorter-lasting.

• Legal Status
  MIPLA is not explicitly scheduled in many jurisdictions but may fall under analog acts due to its similarity to LSD. This makes its sale, possession, or use legally ambiguous in some countries.

• Usage Context
  Today, MIPLA is primarily used in pharmacological research to study serotonergic pathways, hallucinogenic mechanisms, and receptor selectivity in animal models and theoretical neurobiology.

MIPLA and LSD share a similar molecular backbone and generate comparable psychedelic effects. However, differences in potency, duration, and subjective intensity make MIPLA a unique compound within the lysergamide family.

• Potency Differences
  MIPLA is estimated to be roughly one-third to one-half as potent as LSD. A typical active dose of LSD might range from 75–150 µg, while MIPLA may require 200–300 µg for comparable effects.

• Duration and Onset
  MIPLA effects usually last around 6 to 10 hours, which is slightly shorter than LSD’s 8 to 12 hour range. Its onset is similar, generally taking 30–60 minutes to begin.

• Subjective Effects
  Reports describe MIPLA as having a gentler headspace than LSD, with slightly less cognitive complexity or introspective intensity. Visuals and sensory enhancement remain prominent.

• Safety Profile
  Like LSD, MIPLA shows low toxicity and no known lethal dose. However, because it is less studied clinically, caution is advised regarding dosage and combination with other substances.

• Receptor Binding
  Both substances target the 5‑HT2A receptor but may differ in how strongly and for how long they engage the receptor. MIPLA’s altered amide group may influence receptor efficacy and selectivity.

• Research Use
  MIPLA provides researchers a way to study the effects of amide substitutions in the ergoline framework, helping map the structural activity relationships of psychedelic lysergamides.

MIPLA has limited but meaningful applications in the scientific study of psychedelics. It is primarily utilized in preclinical environments to understand how chemical structure affects receptor activity, neurochemical signaling, and subjective experiences in analogs of LSD.

• Receptor Pharmacology Studies
  MIPLA is used in receptor-binding assays, particularly focusing on the 5‑HT2A receptor, which is critical in producing psychedelic effects. Understanding how different amide substitutions affect receptor activation is key to lysergamide research.

• Structure-Activity Relationship (SAR) Exploration
  Researchers examine how MIPLA’s substitution pattern impacts potency, efficacy, and the balance of psychedelic versus non-psychedelic effects, contributing to SAR models of ergolines.

• Animal Behavior Studies
  In rodent models, MIPLA can produce head-twitch responses (HTR), a common proxy for hallucinogenic activity in animals. These models help identify functional agonists at key serotonin receptors.

• Analytical Reference Standard
  MIPLA serves as a reference material in forensic and pharmacological labs. It helps distinguish similar lysergamides in complex analytical environments using chromatography and spectrometry techniques.

• Educational and Forensic Analysis
  Institutions that train analytical chemists or forensic scientists use MIPLA to teach detection, identification, and separation of lysergamides through standard techniques like GC-MS or FT-IR.

• Comparative Toxicology Research
  Though limited, MIPLA contributes to a broader understanding of the safety and metabolism of novel lysergamides by serving as a comparative model in preclinical testing.

The legality of MIPLA varies by country and often falls into a gray area due to its structural similarity to LSD. In many jurisdictions, it is not scheduled by name but may still be considered illegal under analogue legislation, which criminalizes compounds that are chemically or functionally similar to controlled substances.

• Not Internationally Scheduled
  MIPLA is not listed in the United Nations Convention on Psychotropic Substances, so its global control status is inconsistent and dependent on local laws.

• United States (Federal Law)
  While MIPLA is not explicitly scheduled, it is considered an analogue of LSD and may be subject to prosecution under the Federal Analogue Act if intended for human consumption.

• Europe
  Several EU nations treat MIPLA as a controlled substance under blanket bans or psychoactive substance regulations. Countries like the UK have placed many LSD analogs under the Psychoactive Substances Act.

• Australia & New Zealand
  MIPLA may be restricted under analog clauses or pharmacological similarity rulings, even if not directly named in national drug schedules.

• Asia & South America
  Legal status varies significantly. Some countries enforce strict analog rules, while others have no provisions against unscheduled research chemicals.

• Buyer Responsibility
  It is the buyer’s obligation to research and comply with local laws before purchasing MIPLA. Psycho Plug assumes no liability for import issues arising from national regulations.

At Psycho Plug, we offer MIPLA in research-friendly formats optimized for accuracy, stability, and ease of use. Our selection allows customers to choose the format best suited to their analytical, pharmacological, or forensic needs.

• Blotter Paper Format
  Our MIPLA blotters are accurately dosed and professionally printed. Each blotter typically contains between 180–200 µg, suitable for standard lysergamide research models.

• Liquid Solution
  We provide high-purity MIPLA dissolved in ethanol or distilled water, ideal for titration studies or precise receptor-binding experiments. Concentration details are included in every shipment.

• Crystalline Powder (upon request)
  For advanced labs with proper storage and handling facilities, we offer crystalline MIPLA powder in sealed, moisture-proof containers. This format ensures long-term stability.

• Batch Documentation
  Each form is accompanied by lab documentation including HPLC purity results, synthesis date, and compound identity verification.

• Storage Recommendations
  All MIPLA formats should be stored in a dark, cool, and dry environment. For long-term preservation, refrigeration (4°C) is advised.

• Research Use Only
  All forms are intended strictly for research or forensic purposes and are not approved for human consumption.

We ensure that every unit of MIPLA distributed by Psycho Plug is laboratory-verified for purity and quality. As MIPLA is a compound used in pharmacological and analytical research, maintaining an exceptionally high purity level is essential for consistency and reliability in studies.

• ≥98% Research-Grade Purity
  Our MIPLA is consistently tested to be ≥98% pure using advanced chromatography techniques. This level of purity ensures reliable experimental results and minimal presence of side products.

• HPLC and GC-MS Verified
  We utilize High-Performance Liquid Chromatography (HPLC) and Gas Chromatography-Mass Spectrometry (GC-MS) to verify the composition of every batch. These are gold-standard methods used in pharmaceutical quality control.

• Free from Residual Solvents and Impurities
  All MIPLA samples are screened for potential contaminants, including residual solvents and synthesis byproducts. We meet international purity guidelines required for research chemicals.

• Batch-Specific Certificates
  Each shipment comes with a batch-specific Certificate of Analysis (CoA) indicating exact purity, date of analysis, and testing methodology. This allows researchers to verify and document compound quality.

• Consistency Across Batches
  Our synthesis and purification protocols are standardized to ensure minimal variation from batch to batch, which is crucial for reproducibility in scientific research.

• No Added Fillers or Binders
  Unlike some suppliers, we do not use excipients or stabilizers that could alter the chemical behavior of MIPLA. What you receive is pure, unadulterated research compound.

MIPLA should be handled with care, especially since it is a psychoactive lysergamide with potency comparable to other LSD analogs. While Psycho Plug does not condone human consumption, researchers should dose it with precision based on the intended experimental design.

• Typical Active Range
  In human-equivalent models, an active dose of MIPLA is estimated at 180–300 µg. This assumes roughly one-third to half the potency of LSD. Always start with the lowest measurable amount.

• Use Laboratory-Grade Instruments
  For liquid solutions or powders, researchers should use precision microgram scales and micropipettes to ensure accurate dosing. Inaccurate dosing may skew data or create unsafe scenarios.

• Blotter Dosage Information
  Each blotter square provided by Psycho Plug is pre-measured and typically contains 180–200 µg. This allows for uniform research across replicated models.

• Sublingual or Oral Administration (for in-vitro modeling)
  The compound’s behavior under oral or sublingual administration routes is often replicated in receptor modeling or in vitro studies for metabolic and absorption research.

• Not Meant for Human Consumption
  All MIPLA products are labeled “For Research Use Only” and must not be used for any unauthorized or recreational purpose. They are not approved by regulatory bodies for therapeutic use.

• Storage Can Affect Dosing Stability
  Over time, exposure to light, air, or moisture may degrade potency. Doses should be calculated based on verified recent purity data, not assumed strength.

Handling MIPLA, like any psychoactive research chemical, requires strict adherence to laboratory safety protocols. Despite its relatively low toxicity, safety concerns exist due to its potential psychoactivity, legal status, and handling risks.

• Use Personal Protective Equipment (PPE)
  Gloves, goggles, and lab coats should always be worn when handling MIPLA to avoid accidental skin exposure or inhalation of fine particles.

• Work in a Controlled Environment
  All work with MIPLA should take place in a fume hood or well-ventilated laboratory. This prevents airborne particles or vapors from being inhaled and keeps the working space clean.

• Avoid Cross-Contamination
  Always clean surfaces and use dedicated tools when working with MIPLA to avoid cross-contamination with other research substances.

• Secure Storage Protocol
  Store MIPLA in clearly labeled, airtight containers in a cool, dark, and dry location. Access should be restricted to trained personnel only.

• Spill and Exposure Response
  In the event of a spill, absorb with a non-reactive material like activated charcoal and dispose of according to hazardous waste protocols. Accidental skin or eye contact should be rinsed immediately and medical consultation sought if symptoms occur.

• Document Usage and Handling
  Maintain accurate lab notes, including compound quantity used, date, and personnel involved. This ensures traceability and accountability.

In studies and anecdotal reports where MIPLA’s psychoactive profile is observed, the duration is similar to that of classical lysergamides like LSD, though slightly shorter in some cases. While exact timing depends on dosage and individual metabolism, its effects typically unfold over several phases.

• Typical Duration: 6–10 Hours
  MIPLA’s effects usually span 6 to 10 hours. Onset begins between 30–60 minutes post-administration in human analog studies, with peak effects reached around the 2–4 hour mark.

• Milder Plateau Phase
  Compared to LSD, MIPLA often produces a softer plateau phase, which may reduce the cognitive intensity or anxiety associated with peak experiences.

• Gradual Decline
  The comedown is reportedly smooth, with reduced emotional volatility or mental exhaustion. Many users report retaining functional clarity after the peak.

• No Hangover Effect Noted
  Research and anecdotal observations suggest that MIPLA produces minimal aftereffects or “hangover” symptoms in comparison to longer-lasting psychedelics like LSZ or ALD-52.

• Duration Varies with Dose
  Higher doses may extend the experience closer to 10 hours or slightly beyond. Lower doses may result in a noticeably shorter duration.

• Subjective Time Distortion
  As with LSD, MIPLA can cause a perceived stretching or compression of time, making the experience feel longer than its actual duration.

MIPLA is chemically distinct but structurally close to LSD, meaning it typically does not appear on standard drug screening panels used in employment or routine medical testing. However, it can be identified in forensic or specialized toxicology labs.

• Not Included in Basic Drug Panels
  Routine urinalysis panels like 5-panel or 10-panel drug tests do not screen for MIPLA or most research lysergamides. Employers or schools are unlikely to detect it.

• Detectable with Specialized Equipment
  Advanced testing methods such as GC-MS (Gas Chromatography-Mass Spectrometry) or LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry) can accurately detect and quantify MIPLA in biological samples.

• Used as a Forensic Standard
  MIPLA is increasingly added to forensic databases and libraries as part of the expanding list of new psychoactive substances (NPS), especially in Europe and North America.

• Short Detection Window
  Like LSD, MIPLA is usually eliminated from the system within 24–48 hours after use, though metabolites may remain detectable slightly longer depending on dose and frequency.

• Requires Reference Standards
  Laboratories must have specific MIPLA reference standards to calibrate instruments, which limits detection to more advanced or well-funded facilities.

• Legal Context of Detection
  Even if detected, proving intent for human consumption (necessary for analog act enforcement) can be difficult, especially if labeled for research.

MIPLA is considered orally active, as it shares a structural backbone with LSD, which is highly bioavailable through oral and sublingual routes. Although human consumption is not advised or supported by Psycho Plug, oral activity is inferred from the pharmacokinetics observed in lab models and forensic reports involving blotter-based use.

• Orally Bioavailable
  MIPLA is structurally similar to LSD, which undergoes minimal degradation in the digestive system. This makes MIPLA effectively bioavailable when ingested.

• Blotter Administration Evidence
  Forensic analyses of seized blotters containing MIPLA confirm that the compound is absorbed efficiently through the sublingual mucosa, much like LSD.

• Metabolic Pathway Parallels LSD
  MIPLA is expected to undergo first-pass metabolism similar to LSD, producing comparable breakdown products without significant loss of potency.

• Experimental Dosage Confirmation
  In laboratory studies with rodent models and anecdotal human reports, oral or sublingual dosing of 150–300 µg has led to full-spectrum lysergamide responses.

• Route Affects Onset and Duration
  Oral ingestion may delay onset slightly compared to sublingual administration, which provides faster absorption through mucous membranes.

• Liquid Dosing Equivalence
  MIPLA in ethanol-based solutions can be administered under the tongue for rapid absorption, replicating the sublingual route in receptor activation studies.

While MIPLA has not been approved for medical use, its structural and functional similarities to LSD suggest that it may possess some of the same therapeutic mechanisms. Its gentler subjective profile also makes it an intriguing candidate for future clinical exploration, though current data remains preliminary.

• 5-HT2A Agonism and Neuroplasticity
  Like LSD and psilocybin, MIPLA activates 5‑HT2A receptors, which have been linked to increased neuroplasticity, cognitive flexibility, and mood enhancement in therapeutic models.

• Potential for Anxiety and Depression Studies
  Early findings on lysergamide analogs show potential for reducing depressive symptoms, promoting emotional processing, and alleviating anxiety in controlled settings.

• Gentler Cognitive Profile
  MIPLA’s reduced intensity compared to LSD could make it more suitable for therapeutic models that require patient comfort and lower risk of psychological overwhelm.

• Low Toxicity Profile
  Preclinical evidence suggests that MIPLA, like other ergolines, has an extremely low toxicity profile, with no neurotoxic or organ-damaging effects observed in typical doses.

• Non-Habit Forming
  MIPLA does not show addictive properties, reinforcing the therapeutic appeal for controlled, short-term use without dependency concerns.

• Unknown Long-Term Risks
  While promising, MIPLA has not undergone clinical trials or regulatory review. Its therapeutic potential remains speculative until further research validates its safety and efficacy.

EIPLA (ethylisopropyllysergamide) is another close analog of LSD, differing from MIPLA by the substitution of an ethyl group instead of a methyl group at the amide nitrogen. This seemingly small change can significantly affect potency, receptor affinity, and experiential nuances.

• Slightly Higher Potency
  EIPLA is reported to be slightly more potent than MIPLA, with users requiring smaller doses (e.g., 150–250 µg) for comparable effects.

• Similar Duration
  Both MIPLA and EIPLA have similar durations, typically ranging from 6 to 10 hours depending on dose and metabolism.

• Subjective Experience Variations
  While both analogs are LSD-like, EIPLA may exhibit more visual activity and emotional depth, whereas MIPLA is often described as smoother and less intense cognitively.

• Pharmacological Profile
  Both act primarily on 5‑HT2A receptors, but EIPLA may display a slightly different affinity or efficacy due to the ethyl substitution, impacting receptor signaling.

• Availability and Research Status
  EIPLA is less commonly available than MIPLA but has appeared in niche research circles. Its status as a “designer lysergamide” makes it useful for comparative receptor modeling.

• Legal Considerations
  Like MIPLA, EIPLA is not specifically scheduled in most regions but may be controlled under analog laws, particularly where LSD analogs are broadly banned.

LAMPA (methylpropyllysergamide) is a structural isomer within the lysergamide family, differing from MIPLA in the side chain attached to the amide nitrogen. These small structural shifts can dramatically influence the intensity, duration, and receptor dynamics of the compound.

• Weaker Potency
  LAMPA is reported to be significantly less potent than both MIPLA and LSD, with typical effective doses exceeding 300–400 µg. This reduced potency may be due to less efficient receptor binding.

• Shorter Duration
  Effects from LAMPA tend to be shorter, typically lasting 4 to 7 hours. This briefer time frame can be useful in research focusing on acute response windows.

• Reduced Visual and Cognitive Impact
  Users describe LAMPA as producing mild visuals and a calm, slightly euphoric state. It lacks the full intensity and depth of LSD or MIPLA experiences.

• Partial 5‑HT2A Agonist
  Studies suggest that LAMPA functions as a partial agonist at the 5‑HT2A receptor, which may explain its milder psychoactivity compared to MIPLA.

• Analog Research Utility
  LAMPA is valuable in comparative studies investigating how different amide substitutions affect receptor engagement and subjective experiences.

• Lower Popularity and Rarity
  Due to its weak psychoactive effects, LAMPA is less popular among researchers and rarely available through mainstream vendors.

While Psycho Plug ensures every package is shipped discreetly and with proper labeling, international orders are always subject to the import laws and customs policies of the destination country. This means taxes, delays, or even seizures may occur in regions with strict regulations.

• Customs Duties May Apply
  Depending on the destination country, import taxes or VAT may be assessed upon arrival. These fees are typically the responsibility of the recipient.

• Strict Countries May Seize Packages
  In countries with stringent drug analog laws (e.g., Sweden, Japan, Singapore), customs may confiscate MIPLA shipments even if not explicitly listed as illegal.

• Discreet Labeling Reduces Risk
  We use generic product labels and nondescript packaging materials to minimize the chance of inspection or seizure by customs authorities.

• Buyer Is Responsible for Legal Compliance
  Psycho Plug does not assume responsibility for issues arising from local legal restrictions. Customers should research their local laws before placing orders.

• Tracking Helps Monitor Delays
  Every order comes with a tracking number, which allows you to observe whether a package is delayed in customs and follow up with local postal authorities.

• Reshipment May Be Offered
  If a package is proven to be lost or seized and you contact us within 30 days, we may offer a reshipment or partial refund depending on the circumstances.